Trifluorothymidine

• CAT Number: A000501
• CAS Number: 70-00-8
• Molecular Formula: C₁₀H₁₁F₃N₂O₅
• Molecular Weight: 296.20
• Purity: ≥95%
• Synonyms: TRIFLUOROTHYMIDINE; 70-00-8; Viroptic; 5-Trifluorothymidine; Trifluridina
• Target: Anti-infection
• Solubility: >14.5mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
• InChI: InChI=1S/C10H11F3N2O5/c11-10(12,13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2,5-7,16-17H,1,3H2,(H,14,18,19)/t5-,6+,7+/m0/s1
• InChIKey: VSQQQLOSPVPRAZ-RRKCRQDMSA-N
• SMILES: C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O

Trifluridine (also called trifluorothymidine or TFT) (Cat No.: A000501) is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name, Viroptic, by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now owned by Monarch Pharmaceuticals, which is wholly owned by King Pharmaceuticals. It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the -CF3 group added to the uracil component blocks base pairing. It is a component of the experimental anti-cancer drug TAS-102.